Pharming Submits Human Recombinant C1 Inhibitor To EMEA
This article was originally published in The Pink Sheet Daily
The transgenic rabbit-produced biologic could prove controversial.
You may also be interested in...
Second-generation C1 inhibitor has “tremendous body of safety and efficacy data” behind it from decades of use in Europe, CEO tells “The Pink Sheet” DAILY.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.